OS Therapies Raises Capital Through Warrant Inducement Agreements

OS Therapies Incorporated ( (OSTX) ) just unveiled an announcement.

On January 10, 2026, OS Therapies entered into warrant inducement agreements with nine accredited investors holding existing warrants, securing the exercise or pre‑funding of all such warrants at a reduced $1.40 exercise price in exchange for new five‑year warrants on the same pricing terms. The transaction, announced on January 12, 2026 and supported by Ceros Capital Markets as solicitation agent, generated approximately $7.53 million in gross proceeds, extending the company’s cash runway into 2027 and funding regulatory submissions and commercial preparations for OST‑HER2 in metastatic osteosarcoma across the U.S., U.K. and EU, as well as preparations for the proposed spinoff of its OS Animal Health subsidiary and general corporate needs, thereby strengthening its balance sheet and addressing prior market concerns about liquidity while deepening backing from long‑term investors.

The most recent analyst rating on (OSTX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.

Spark’s Take on OSTX Stock

According to Spark, TipRanks’ AI Analyst, OSTX is a Neutral.

The score is primarily weighed down by weak financial performance (no revenue, expanding losses, and ongoing cash burn), with bearish technicals reinforcing downside pressure. A debt-free balance sheet and recent corporate actions that improve financing flexibility provide some support, but dilution risk and lack of earnings-based valuation anchors keep the score low.

To see Spark’s full report on OSTX stock, click here.

More about OS Therapies Incorporated

OS Therapies Inc. is a clinical-stage oncology company and a self-described world leader in listeria‑based cancer immunotherapies, focused on developing and commercializing treatments for osteosarcoma and other solid tumors. Its lead asset, OST‑HER2, is an immunotherapy targeting the HER2 protein that has shown positive Phase 2b data in recurrent, fully resected, lung metastatic osteosarcoma and carries Rare Pediatric Disease, Fast Track and Orphan Drug designations from U.S. and European regulators; the company is also advancing a tunable antibody-drug conjugate platform and operates an animal health subsidiary with a conditionally approved canine osteosarcoma therapy.

Average Trading Volume: 365,306

Technical Sentiment Signal: Sell

Current Market Cap: $54.23M

For detailed information about OSTX stock, go to TipRanks’ Stock Analysis page.